Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Recurrent Clear Cell Ovarian Cancer
NCT02315430Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2015
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in ovarian clear cell carcinoma (OCCC), fallopian tube cancer (PFTC), primary peritoneal clear cell carcinoma (PPCCC), sponsored by National Cancer Institute. Started Apr 2015; status: completed.
02
Drugs
cabozantinib
03
Conditions
ovarian clear cell carcinoma (OCCC)fallopian tube cancer (PFTC)primary peritoneal clear cell carcinoma (PPCCC)
Beyond the preview
Go deeper on NCT02315430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315430.